Characterization of the oral and gut microbiota in patients with psoriatic diseases: A systematic review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 492 KB, PDF-dokument
Advances in technology have led to an increased number of studies investigating the microbiome in patients with psoriasis. This systematic review examined data regarding the oral and gut microbiota in patients with psoriasis and/or psoriatic arthritis and the effect of probiotics on the microbiota and severity of psoriasis. Of 1,643 studies, 23 were included (22 observational, 1 interventional). Studies examined the microbiota using culture or 16S rRNA gene sequencing analysis. All culture-based studies identified an increased presence of oral Candida in patients with psoriasis, whereas small variations in the oral microbiota were found in a 16S rRNA gene-based study. All 16S rRNA gene sequencing based studies agreed that the gut microbiota of patients with psoriatic disease differed from that of healthy controls, but the results were heterogeneous. Probiotics were associated with a significant improvement in the severity of psoriasis, but did not change microbiota. Overall, studies lacked relevant inclusion criteria and baseline information. In conclusion, the role of the microbiota in patients with psoriasis requires further investigation using more robust methods.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | adv00512 |
| Tidsskrift | Acta Dermato-Venereologica |
| Vol/bind | 101 |
| Udgave nummer | 7 |
| Antal sider | 10 |
| ISSN | 0001-5555 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
for Novartis, Abbvie, Dr Wolff and Almirall. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Co., Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals. CZ has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novartis, Sanofi, Leo Pharma, UCB, CSL and Almirall. ASHO has received honoraria as speaker for Leo Pharma and consultant for Coloplast A/S. LS has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novartis, Sanofi, Celegene, Leo Pharma, BMS, UCB and Almirall, outside the submitted work. LS reports non-financial support from Abbvie, Sanofi, Janssen and grants from Novartis, Janssen, BMS and Sanofi.
Funding Information:
This study was supported by Aage Bangs Foundation.
Publisher Copyright:
© 2021, Medical Journals/Acta D-V. All rights reserved.
ID: 289463022